| Project/Area Number |
24790357
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
YASUOKA Hironao 和歌山県立医科大学, 医学部, 博士研究員 (30405419)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | podocalyxin / 甲状腺癌 / 子宮体癌 / 甲状腺未分化癌 |
|---|
| Research Abstract |
I tried to clarify a role of PODXL in thyroid anaplastic carcinoma and other carcinomas. In thyroid cancer, PODXL and phosphorylated ezrin expression were related to anaplastic transformation. also, it related with regional extension and lymph node metastases. In uterine endometrial adenocarcinomas, PODXL and phosphorylated ezrin expression related with the status of malignancy marker, a histological grade and clinical stage. Enforced expression of PODXL in several established human thyroid cancer cell lines, increasing of growth fractions and invasiveness and increasing of mortility were induced. PODXL and phosphorylated ezrin were coexpressed at foot process of the cultured cells.
|
